You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report
|
|---|---|
| Published in |
BMC Neurology, December 2015
|
| DOI | 10.1186/s12883-015-0512-0 |
| Pubmed ID | |
| Authors |
Francesco Patti, Carmela Leone, Mario Zappia |
| Abstract |
The evidence on the use of the oral dimethyl-fumarate after the discontinuation of treatment with natalizumab in people with Multiple Sclerosis is still little. Natalizumab discontinuation may induce the recurrence or rebound of the clinical and neuroradiological disease activity. Currently no therapeutic approach has been established to abolish disease reactivation and rebound after natalizumab interruption. We describe a case of a 21-year-old woman affected from a highly active relapsing-remitting Multiple Sclerosis who developed a clinical and radiological rebound 5 months after the last infusion of natalizumab, while she was being treated with dimethyl-fumarate 240 mg twice daily. She had received a bridge "therapy" with Cyclophosphamide before staring dimethyl-fumarate. We report on this case to stimulate further research to establish whether new current and future drugs available for multiple sclerosis are able to halt the disease rebound after the natalizumab interruption. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 2% |
| Unknown | 42 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 6 | 14% |
| Other | 4 | 9% |
| Student > Ph. D. Student | 3 | 7% |
| Student > Postgraduate | 3 | 7% |
| Student > Master | 3 | 7% |
| Other | 9 | 21% |
| Unknown | 15 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 35% |
| Neuroscience | 4 | 9% |
| Psychology | 4 | 9% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Immunology and Microbiology | 1 | 2% |
| Other | 0 | 0% |
| Unknown | 17 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 December 2015.
All research outputs
#3,271,381
of 22,835,198 outputs
Outputs from BMC Neurology
#417
of 2,436 outputs
Outputs of similar age
#58,359
of 388,302 outputs
Outputs of similar age from BMC Neurology
#10
of 50 outputs
Altmetric has tracked 22,835,198 research outputs across all sources so far. Compared to these this one has done well and is in the 85th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,436 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.7. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 388,302 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.